Brief: Zealand Pharma Outlines Metabolic Frontier 2030 Strategy

Zealand Pharma A/S

11/12/2025 06:14

Dec 11 (Reuters) - Zealand Pharma A/S ZELA.CO:

OUTLINES METABOLIC FRONTIER 2030 STRATEGY

TARGETS FIVE LAUNCHES, +10 CLINICAL PIPELINE PROGRAMS, AND INDUSTRY-LEADING CYCLE TIMES FROM IDEA TO CLINIC BY 2030

CATALYST-RICH 2026 WITH MULTIPLE CLINICAL READOUTS, INCLUDING PHASE 2 DATA WITH PETRELINTIDE IN Q1 2026 AND PHASE 3 OBESITY DATA WITH SURVODUTIDE THROUGHOUT 2026

Source text: ID:nGNE7lbXC2

Further company coverage: ZELA.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))